June 26, 2024
1 min read

India’s Pharma to Hit Rs 5.5 Trillion

The report showed that currently the market is valued at Rs 2 trillion, with a growth rate of 11 per cent over the last 20 years….reports Asian Lite News

India’s Domestic Pharma Formulations (DomForm) market, which includes branded generic medicines, is expected to more than double and cross Rs 5.5 trillion in the next 10 years at a CAGR of 10 per cent, according to a new report.

The report, by investment banking firm Avendus Capital, showed that currently the market is valued at Rs 2 trillion, with a growth rate of 11 per cent over the last 20 years.

However, with a gradual transition from a primarily doctor-branded prescription model, more stringent quality compliance, and government policies and regulatory measures, the market is expected to make a significant growth.

“We are encouraged by the government of India’s Pharma Vision 2047, which is aimed at making medicines more equitable, accessible, and affordable while ensuring high quality and more sustainable manufacturing practices. We believe that the sector will more than double from today, comfortably crossing about Rs 5.5 trillion in value by 2034,” the report said.

The report also predicted shifts in channel volumes, with trade generics and the unbranded “Generic Generics”, including Jan Aushadhi centres and government hospital procurement, gaining more traction.

“We estimate that the DomForm market will continue growing at 9-10 per cent CAGR in the next 10 years. With the expansion of trade generics and Jan Aushadhi channels, we expect about 30 per cent volume contribution from these in 10 years,” the report said.

Although off-patent generics currently account for nearly 100 per cent of the market, because of local manufacturing and process innovations, the prices of medicines are significantly lower than the global average.

Currently, more than 3,000 companies and almost 10,000 manufacturing units exist, yet they come with significant variations in quality standards.

Substandard, spurious and counterfeit drugs account for a staggering 20 per cent of the market, as per official testing.

ALSO READ: India’s Capex Fuels Capital Goods Surge

Previous Story

India’s Wedding Market Now $130 Billion

Next Story

Farakka treaty: Centre denies claim of not consulting Bengal

Latest from Business

SBI Simplifying KYC Process

SBI’s research arm noted that the RBI’s decision to maintain the policy rate reflects a balanced approach amid global uncertainties, supported by stable liquidity and external conditions State Bank of India (SBI)

UPI Powers Digital Revolution

New innovations such as LiteX (offline payments), tap-and-pay, credit card integration, UPI Autopay, and UPI for IPO subscriptions are pushing the platform from a payment tool to a full-fledged embedded finance ecosystem Unified

RBI Holds Rates, Boosts Outlook

One of the most significant announcements was the upward revision of India’s GDP growth forecast for FY 2025–26—from 6.5% to 6.8% In a move reflecting cautious optimism, the Reserve Bank of India

Nykaa Expands Global Footprint with UK Debut

To commemorate this significant global debut, Nykaa’s leadership hosted an exclusive soiree at the George Club in Mayfair, London Nykaa, India’s leading beauty and lifestyle destination, is set to make a grand
Go toTop

Don't Miss

Foreign Secretary Kwatra meets Myanmar military leaders

The friendship between India and Myanmar is age-old and has

Mobile internet suspended in Kashmir Valley

Deployment has also been strengthened in other parts of the